Invest Daily Pro
  • Economy
  • Investing
No Result
View All Result
  • Economy
  • Investing
No Result
View All Result
Invest Daily Pro
No Result
View All Result
Home Investing

Top 5 Canadian Biotech Stocks in 2025

by Invest Daily Pro
April 23, 2025
in Investing
0
Top 5 Canadian Biotech Stocks in 2025
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

According to Grandview Research, the global biotech market is expected to grow at a compound annual growth rate of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

Read on to learn what’s been driving these Canadian biotech firms.

1. Bright Minds Biosciences (CSE:DRUG)

Year-on-year gain: 2,681.82 percent
Market cap: C$322.61 million
Share price: C$45.90

Bright Minds Biosciences is focused on developing novel treatments for neuropsychiatric disorders and pain.

Its portfolio consists of serotonin agonists designed to target neurocircuit abnormalities that make disorders like epilepsy, post-traumatic stress disorder and depression difficult to treat. The company’s drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing their side effects, thereby creating superior drugs to first-generation compounds such as psilocybin.

In October 2024, the company’s share price surged nearly 1,500 percent in a single session after global pharmaceutical company H. Lundbeck announced its intention to acquire Longboard Pharmaceuticals. Both Longboard and Bright Minds have agonists targeting the 5-HT2C receptorin their pipelines.

Bright Minds’ 5-HT2C agonist candidate, BMB-101, will target classic absence epilepsy and developmental epileptic encephalopathy. The company is currently evaluating Phase II trials in collaboration with Firefly Neuroscience (NASDAQ:AIFF).

In March of this year, Bright Minds added five world-renowned leaders in epilepsy research to its scientific advisory board.

2. ME Therapeutics Holdings (CSE:METX)

Year-on-year gain: 145.9 percent
Market cap: C$235.71 million
Share price: C$9.00

ME Therapeutics is a biotechnology company focused on developing cancer-fighting drug candidates that can increase the efficacy of current immuno-oncology drugs by targeting suppressive myeloid cells, which have been found to hinder the effectiveness of existing immuno-oncology treatments. Immuno-oncology is a relatively new area of cancer drug research and has shown promising results when used to treat cancer with low survival rates.

In December 2023, the company shared research done in collaboration with Dr. Kenneth Harder at the University of British Columbia. The work suggests that ME Therapeutics’ antibody, h1B11-12, successfully blocks a protein that fuels breast and colon cancer growth (G-CSF). Trial planning efforts are ongoing, and the company expects development of a cell line for future production of the drug to be finished in the latter half of 2025.

In addition, the company is part of an ongoing collaborative effort to develop therapeutic MRNA delivery methods to myeloid cells with NanoVation Therapeutics, a privately owned biotech company that develops customized nucleic acid and lipid nanoparticle technologies to empower genetic medicine.

The collaboration has already resulted in two new MRNA formulations, for which testing began on October 4, and has demonstrated encouraging anti-cancer activity in a preclinical model of colorectal cancer.

On March 3, ME Therapeutics shared that it is exploring a listing on the Nasdaq or the New York Stock Exchange.

3. Hemostemix (TSXV:HEM)

Year-on-year gain: 80 percent
Market cap: C$13.36 million
Share price: C$0.09

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, an approach that uses a patient’s own cells to theoretically enhance safety and efficacy. Its main product, ACP-01, is a cell therapy derived from a patient’s blood to promote tissue repair and regeneration in areas affected by disease.

The company announced its first sales orders for ACP-01 on January 29 and has been working to expand internationally and attract new investment.

Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia. As of writing, efforts to fully enroll the trial to its target size are underway.

4. Eupraxia Pharmaceuticals (TSX:EPRX)

Year-on-year gain: 17.07 percent
Market cap: C$173.51 million
Share price: C$5.28

Eupraxia Pharmaceuticals focuses on developing locally delivered therapeutics for patients with unmet medical needs. Its primary focus has been orthopedics and oncology. Eupraxia acquired EpiPharma Therapeutics in late 2023, absorbing the company’s lead candidate EP-104GI.

In February, the company released positive data from the sixth cohort of its Phase 1b/2a trial for EP-104GI in eosinophilic esophagitis. It plans to release additional data periodically, with 12 week data for the trial’s seventh cohort expected in late Q2 2025.

5. Microbix Biosystems (TSX:MBX)

Year-on-year gain: 4.48 percent
Market cap: C$48.17 million
Share price: C$0.35

Microbix Biosystems manufactures antigens and quality control products used in the development of diagnostic tests. They also develop products to ensure test accuracy.

In January, Microbix partnered with the American Proficiency Institute to launch a pilot program to validate the accuracy of molecular assays in testing the H5N1 strain of the influenza A virus.

In March, the company joined the EPICC HPV Elimination Partnership to support test accuracy by supplying materials to support the accuracy of HPV testing efforts. These strategic collaborations highlight the company’s commitment to ensuring reliable and accurate diagnostic testing worldwide.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Keep reading…Show less
This post appeared first on investingnews.com

ShareTweetPin

Related Posts

Top 10 Uranium-producing Countries
Investing

Top 10 Uranium-producing Countries

June 3, 2025
Development update – Collie graphite micronising facility
Investing

Development update – Collie graphite micronising facility

June 3, 2025
Blue Lagoon’s Dome Mountain Joins BC’s Select List of Permitted Projects
Investing

Blue Lagoon’s Dome Mountain Joins BC’s Select List of Permitted Projects

June 2, 2025
Harmony Gold to Acquire MAC Copper in US$1.03 Billion Deal
Investing

Harmony Gold to Acquire MAC Copper in US$1.03 Billion Deal

June 2, 2025
Editor’s Picks: Gold Faces Bumpy Week on Trade Tensions, Platinum Stages Breakout
Investing

Editor’s Picks: Gold Faces Bumpy Week on Trade Tensions, Platinum Stages Breakout

June 1, 2025
Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain
Investing

Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

May 31, 2025
Next Post
$4,000 Gold? Analysts Eye New Highs on Inflation and Geopolitical Risk

$4,000 Gold? Analysts Eye New Highs on Inflation and Geopolitical Risk

Recommended

KUKA HOME is now at OUR HOME

KUKA HOME is now at OUR HOME

October 31, 2024
Bespoke Biologix Attracts U.S. Patients Seeking Advanced Stem Cell Therapies in Mexico

Bespoke Biologix Attracts U.S. Patients Seeking Advanced Stem Cell Therapies in Mexico

August 19, 2024
What to Consider When Selecting Healthcare Payment Solutions

What to Consider When Selecting Healthcare Payment Solutions

October 7, 2024
Balancing Fitness, Work, and Mindful Snacking

Balancing Fitness, Work, and Mindful Snacking

September 20, 2024
Gov’t fully awards T-bills at mostly higher rates

Gov’t fully awards T-bills at mostly higher rates

August 5, 2024
First Asia K-Banker School empowers global leaders in digital finance

First Asia K-Banker School empowers global leaders in digital finance

November 20, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 InvestDailyPro. All Rights Reserved.

    Disclaimer: InvestDailyPro.com, its managers, its employees, and assigns (collectively InvestDailyPro ) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
    The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    No Result
    View All Result
    • About us
    • Contact us
    • Home
    • Privacy Policy
    • Suspicious engagement
    • Terms & Conditions
    • Terms & Conditions
    • Thank you

    Copyright © 2024 investdailypro.com | All Rights Reserved